Real-World Evidence of Dydrogesterone 20 mg and 30 mg SR Usage in Pregnancy

Background Dydrogesterone, an oral selective progesterone receptor agonist with high bioavailability, has been used since the 1960s to treat various conditions arising due to the deficiency of progesterone. Patients are expected to have additional compliance and reduced pill burden with dydrogesterone 20 mg and 30 mg SR once a day (OD) for conditions requiring 10 mg twice a day (BID) or thrice a day (TID). Methodology A real-world analysis was conducted using the HealthPlix electronic medical records (EMR) database to understand the demography, indications, and prescription patterns of dydrogesterone 20 mg and 30 mg SR, including co-prescriptions. Results The mean age of the female patients prescribed dydrogesterone 20 mg SR was 27.23 ± 4.79 years while those prescribed 30 mg SR had a mean age of 28.56 ± 5.17 years. Common indications for the prescription of dydrogesterone 20 mg SR were pregnancy, infertility, and abortion/miscarriage. Pregnancy, infertility, and amenorrhea were the common conditions for dydrogesterone 30 mg SR prescription. The average duration of prescription of dydrogesterone 20 mg and 30 mg SR was 55.50 ± 31.33 and 79.66 ± 68.38 days, respectively. OD regimen was the preferred regimen for dydrogesterone 20 mg SR (89.48%) and dydrogesterone 30 mg SR (64.06%). Conclusions This analysis suggests dydrogesterone 20 mg and 30 mg SR are being prescribed for various indications in the real world with significant variation in the prescription patterns.